Candida bloodstream infections in Italy: Changing epidemiology during 16 years of surveillance

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Caggiano, Giuseppina ^a   Coretti, Caterina ^a   Bartolomeo, Nicola ^a   Lovero, Grazia ^a   De Giglio, Osvalda ^a   Montagna, Maria Teresa ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOODSTREAM INFECTION; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHILD; EPIDEMIC; FEMALE; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; INCIDENCE; INTENSIVE CARE UNIT; ITALY; MALE; MEYEROZYMA GUILLIERMONDII; MORTALITY; NONHUMAN; PATIENT MONITORING; SPECIES DISTRIBUTION; SYSTEMIC MYCOSIS; ANTIFUNGAL RESISTANCE; CANDIDIASIS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY;

CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS;

ADULT; AGED; CANDIDA ALBICANS; CANDIDEMIA; CANDIDIASIS; CHILD; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED;

EID: 84929649971     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/256580     Document Type: Article

References (30)

1. D. Diekema, S. Arbefeville, L. Boyken, J. Kroeger, and M. Pfaller, "The changing epidemiology of healthcare-associated candidemia over three decades, " Diagnostic Microbiology and Infectious Disease, vol. 73, no. 1, pp. 45-48, 2012.
2. R. Ben-Ami, M. Weinberger, R. Orni-Wasserlauff et al., "Time to blood culture positivity as a marker for catheter-related candidemia, " Journal of Clinical Microbiology, vol. 46, no. 7, pp. 2222-2226, 2008.
3. H. Wisplinghoff, T. Bischoff, and S. M. Tallent, "Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study, " Clinical Infectious Diseases, vol. 9, pp. 309-317, 2004.
4. J. Ericsson, E. Chryssanthou, L. Klingspor et al., "Candidaemia in Sweden: a nationwide prospective observational survey, " ClinicalMicrobiology and Infection, vol. 19, no. 4, pp. E218-E221, 2013.
5. M. A. Pfaller and D. J. Diekema, "Epidemiology of invasive candidiasis: a persistent public health problem, " ClinicalMicrobiology Reviews, vol. 20, no. 1, pp. 133-163, 2007.
6. J. Pemán, E. Cantón, G. Quindós et al., "Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey, " Journal of Antimicrobial Chemotherapy, vol. 67, no. 5, pp. 1181-1187, 2012.
7. J. Kriengkauykiat, J. I. Ito, and S. S. Dadwal, "Epidemiology and treatment approaches in management of invasive fungal infections, " Clinical Epidemiology, vol. 3, no. 1, pp. 175-191, 2011.
8. F. G. de Rosa, E. M. Trecarichi, C. Montrucchio et al., "Mortality in patients with early-or late-onset candidaemia, " Journal of Antimicrobial Chemotherapy, vol. 68, no. 4, pp. 927-935, 2013.
9. M. A. Pfaller, D. Andes, M. C. Arendrup et al., "Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria, " Diagnostic Microbiology and Infectious Disease, vol. 70, no. 3, pp. 330-343, 2011.
10. M. A. Pfaller and D. J. Diekema, "Microdilution methods, 2010 to 2012 and laboratory standards institute broth testing of Candida spp. by use of clinical progress in antifungal susceptibility, " Journal of ClinicalMicrobiology, vol. 50, no. 9, pp. 2846-2856, 2012.
11. M. A. Pfaller, D. J. Diekema, R. N. Jones et al., "International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program, " Journal of Clinical Microbiology, vol. 39, no. 9, pp. 3254-3259, 2001.
12. D. J. Diekema, S. A. Messer, L. B. Boyken et al., "In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods, " Journal of ClinicalMicrobiology, vol. 47, no. 10, pp. 3170-3177, 2009.
13. Clinical and Laboratory Standards Institute, "Reference method for broth dilution antifungal susceptibility testing of yeasts-third informational supplement, " Tech. Rep. M27-A3, CLSI, Wayne, Pa, USA, 2008.
14. M. C. Arendrup, B. Bruun, J. J. Christensen et al., "National surveillance of fungemia in Denmark (2004 to 2009), " Journal of Clinical Microbiology, vol. 49, no. 1, pp. 325-334, 2011.
15. G. Rennert, H. S. Rennert, S. Pitlik, R. Finkelstein, andR. Kitzes-Cohen, "Epidemiology of candidemia-a nationwide survey in Israel, " Infection, vol. 28, no. 1, pp. 26-29, 2000.
16. D. Li, W. Zhang, S. Zheng, Z. Ma, P. Zhang, and Z. Liu, "Surveillance study of candidemia in cancer patients in North China, " Medical Mycology, vol. 51, no. 4, pp. 378-384, 2013.
17. I. Faria-Ramos, J. Neves-Maia, E. Ricardo et al., "Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey, " European Journal of Clinical Microbiology & Infectious Diseases, vol. 33, no. 12, pp. 2241-2247, 2014.
18. A. L. Motta, G. M. D. de Almeida, J. N. de Almeida Jr., M. N. Burattini, and F. Rossi, "Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex, " Brazilian Journal of Infectious Diseases, vol. 14, no. 5, pp. 441-448, 2010.
19. M. T. Montagna, G. Lovero, O. De Giglio et al., "Invasive fungal infections in Neonatal Intensive Care Units of Southern Italy: a multicentre regional active surveillance (Aurora Project), " Journal of Preventive Medicine and Hygiene, vol. 51, no. 3, pp. 125-130, 2010.
20. M. T. Montagna, O. de Giglio, C. Napoli et al., "Invasive fungal infections in patients with hematologic malignancies (Aurora Project): lights and shadows during 18-months surveillance, " International Journal of Molecular Sciences, vol. 13, no. 1, pp. 774-787, 2012.
21. M. T. Montagna, G. Caggiano, G. Lovero et al., "Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project), " Infection, vol. 41, no. 3, pp. 645-653, 2013.
22. H. Wisplinghoff, J. Ebbers, L. Geurtz et al., "Nosocomial bloodstreaminfections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities, " International Journal of Antimicrobial Agents, vol. 43, no. 1, pp. 78-81, 2014.
23. A. Spiliopoulou, S. Vamvakopoulou, C. Bartzavali, G. Dimitracopoulos, E. D. Anastassiou, andM. Christofidou, "Eleven-year retrospective survey of candidaemia in a university hospital in southwestern Greece, " Clinical Microbiology and Infection, vol. 16, no. 9, pp. 1378-1381, 2010.
24. J. Guinea, Ó. Zaragoza, P. Escribano et al., "Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011, " Antimicrobial Agents and Chemotherapy, vol. 58, no. 3, pp. 1529-1537, 2014.
25. E. Matsumoto, L. Boyken, S. Tendolkar et al., "Candidemia surveillance in Iowa: emergence of echinocandin resistance, " DiagnosticMicrobiology and InfectiousDisease, vol. 79, no. 2, pp. 205-208, 2014.
26. F. Barchiesi, G. Caggiano, L. F. Di Francesco, M. T. Montagna, S. Barbuti, and G. Scalise, "Outbreak of fungemia due to Candida parapsilosis in a pediatric oncology unit, " Diagnostic Microbiology & Infectious Disease, vol. 49, no. 4, pp. 269-271, 2004.
27. J. C. O. Sardi, L. Scorzoni, T. Bernardi, A. M. Fusco-Almeida, and M. J. S. Mendes Giannini, "Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options, " Journal of Medical Microbiology, vol. 62, supplement 1, pp. 10-24, 2013.
28. M. A. Pfaller, M. Castanheira, S. A. Messer, G. J. Moet, and R. N. Jones, "Variation in Candida spp. distribution and antifungal resistance rates among bloodstreaminfection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009), " Diagnostic Microbiology and Infectious Disease, vol. 68, no. 3, pp. 278-283, 2010.
29. M. A. Pfaller, D. R. Andes, D. J. Diekema et al., "Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2, 496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008, " PLoS ONE, vol. 9, no. 7, Article ID e101510, 2014.
30. B. D. Alexander, M. D. Johnson, C. D. Pfeiffer et al., "Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations, " Clinical Infectious Diseases, vol. 56, no. 12, pp. 1724-1732, 2013.